Robyn Karnauskas
Stock Analyst at Truist Securities
(1.86)
# 3,227
Out of 4,981 analysts
181
Total ratings
41.77%
Success rate
-1.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRML Tourmaline Bio | Downgrades: Hold | $63 → $48 | $47.61 | +0.82% | 3 | Sep 10, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $4.47 | +123.71% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $276.39 | +7.82% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $46.20 | +40.69% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $82.81 | +32.83% | 11 | Jan 8, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,033 → $1,029 | $755.39 | +36.22% | 5 | Oct 31, 2024 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $114.55 | -27.54% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $218.34 | -3.82% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.93 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $144.86 | +134.71% | 17 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 | $1.80 | +1,348.47% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.29 | +442.64% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $560.00 | +102.68% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.64 | +509.76% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.55 | +252.94% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $14.08 | +63.35% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $16.16 | +197.03% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $11.52 | +334.03% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $394.53 | +28.76% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $23.87 | +50.82% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $61.11 | -59.09% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.11 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $54.09 | +158.83% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $3.86 | +777,102.07% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $0.96 | +626.82% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $16.49 | +233.64% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $23.96 | +1,235.56% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $9.25 | +62.16% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.42 | +20,109.22% | 1 | Oct 8, 2020 |
Tourmaline Bio
Sep 10, 2025
Downgrades: Hold
Price Target: $63 → $48
Current: $47.61
Upside: +0.82%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $4.47
Upside: +123.71%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $276.39
Upside: +7.82%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $46.20
Upside: +40.69%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $82.81
Upside: +32.83%
Eli Lilly and Company
Oct 31, 2024
Maintains: Buy
Price Target: $1,033 → $1,029
Current: $755.39
Upside: +36.22%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $114.55
Upside: -27.54%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $218.34
Upside: -3.82%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.93
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $144.86
Upside: +134.71%
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.80
Upside: +1,348.47%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.29
Upside: +442.64%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $560.00
Upside: +102.68%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.64
Upside: +509.76%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.55
Upside: +252.94%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $14.08
Upside: +63.35%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $16.16
Upside: +197.03%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $11.52
Upside: +334.03%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $394.53
Upside: +28.76%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $23.87
Upside: +50.82%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $61.11
Upside: -59.09%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $3.11
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $54.09
Upside: +158.83%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $3.86
Upside: +777,102.07%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $0.96
Upside: +626.82%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $16.49
Upside: +233.64%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $23.96
Upside: +1,235.56%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $9.25
Upside: +62.16%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.42
Upside: +20,109.22%